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Background: Although stent assisted angioplasty is an effective treatment for coronary and peripheral
arterial disease, its efficacy in intracranial arteriosclerotic disease has not been verified.
Objectives: To assess the radiographic and clinical outcome of stent assisted angioplasty for symptomatic
middle cerebral artery (MCA) stenosis.
Methods: We attempted stent assisted angioplasty in 14 patients with symptomatic high grade stenosis
(.60%) on the proximal portion of the MCA, who had experienced either recurrent transient ischaemic
attacks (TIAs) resistant to medical therapy or one or more stroke attacks. Patient records were analysed for
angiographic characteristics, degree of stenosis, pre-procedural regimen of anti-platelet and/or anti-
coagulation agents, use of devices, procedure related complications, pre-operative and post-operative
single photon emission computed tomography (SPECT) findings, and clinical and radiographic outcomes.
Results: Stent assisted angioplasty was successfully performed in 8 of 14 patients without any serious
complications and unsuccessful in 2 of 14 patients due to the tortuous curve of the internal carotid artery
siphon. Four patients had complications. Two patients had an arterial rupture; one patient was rescued by
an additional stent and balloon tamponade, the other patient died. Complications in the other two patients
included thrombotic occlusion and distal thrombosis. Residual stenosis was less than 50% in diameter in all
the patients. All eight patients who underwent follow up cerebral angiography had no restenosis. Follow
up SPECT showed improved perfusion in the affected MCA territory in all the tested patients with TIA and in
one of three stroke patients. Using the modified Rankin Scale at follow up, four of five TIA patients and five
of six stroke patients were assessed as functionally improved or having a stable clinical status.
Conclusion: Although the re-stenosis rate in stent assisted angioplasty seems to be better than in primary
balloon angioplasty as reported previously, the complication rate is still high. Elective stenting is an
alternative therapeutic method for the prevention of secondary ischaemic stroke in stroke patients with
MCA stenosis, and seems to be a potentially effective but also hazardous therapeutic technique in patients
with recurrent TIAs. This study indicates the need for randomised control trial data of this intervention.
Additionally, long term follow up data and additional clinical experience are required to assess the
durability of this procedure.
T
he most recognised stroke syndromes occur in the middle
cerebral artery (MCA) region, in large part related to the
extensive MCA blood supply to the lateral hemisphere
and deep basal ganglia area. Although embolism is the
predominant mechanism affecting the MCA, primary arterio-
sclerosis at this site occurs in African Americans and Asians
and may play a significant role in MCA occlusive disease,
compared with whites.1 2 Many patients with this disease
have recurrent cerebral ischaemic events despite standard
medical therapy with anti-platelet agents or oral anti-
coagulants. In the Extracranial/Intracranial Bypass Trial,
patients with symptomatic MCA stenosis randomised to
medical therapy had annual ipsilateral stroke rates of 7.8%
and total stroke rates of 9.5%.3 4 Only about one third of
patients had a warning transient ischaemic attack (TIA) prior
to stroke.3 The most common presentation was a stroke
attack without a warning TIA.
In these patients, the stenosis had been slowly growing as
a result of an arteriomatous rather than a thrombotic process.
Anticoagulants would therefore appear to aid only in
prevention of an abrupt final occlusion caused by thrombus,
and not in preventing progression of the disease to an
inevitable occlusion.5 The high recurrent stroke rates indicate
the need for more for more aggressive treatment methods for
patients with symptomatic MCA arteriosclerotic stenosis.
Percutaneous transluminal angioplasty (PTA) has recently
been proposed as a promising treatment for patients with
ongoing cerebral ischaemic events despite standard medical
therapy.5–8 However, PTA has had the problems of abrupt
closure due to complications such as intimal damage, elastic
recoil, and thrombosis.5 7 Abrupt closure in the MCA often
cannot be tolerated, resulting in stroke or death. Stents have
improved these complications in other vascular beds,9 and
advantages of stent assisted angioplasty include exclusion of
the plaque and regions of dissection from the vessel lumen,
and prevention of vessel recoil and rupture.10 Therefore, the
availability of recently introduced flexible stents, the devel-
opment of potent antiplatelet inhibitors, and increasing
evidence from experimental and clinical studies of intra-
cranial stents have encouraged the use of stents in the
management of ischaemic intracranial cerebrovascular dis-
ease.10 11–14
The purpose of this study was to investigate the effective-
ness, safety, and short term outcome of stent placement for
Abbreviations: ICA, internal carotid artery; MCA, middle cerebral
artery; PTA, percutaneous transluminal angioplasty; SPECT, single
photon emission computed tomography; TIA, transient ischaemic attack
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the treatment of refractory symptomatic MCA arteriosclerotic
stenosis.
METHODS
During a 35 month study period between February 2000 and
September 2002, 14 consecutive Asian patients underwent
planned stent assisted angioplasty of symptomatic arterio-
sclerotic stenosis of the MCA. Significant stenosis was
defined as 60–99% stenosis on angiograms. Arteriosclerotic
lesions were classified, according to the method of Mori et al,8
into three groups on the basis of lesion morphology. Patients
were included if they had one of the following three
conditions: (a) recurrent TIAs referable to MCA stenosis that
were unresponsive to medical therapy using therapeutic dose
of aspirin, ticlopidine, clopidogrel, or warfarin; (b) significant
perfusion problems in MCA regions evidenced by decreased
perfusion reserve on single photon emission computed
tomography (SPECT); and (c) infarction at the border zone
of the MCA region, which was considered to be related to
haemodynamic insufficiency. Exclusion criteria were: (a)
presence of significant arteriosclerotic lesions in the arteries
proximal to the MCA; (b) emboligenic heart disease; (c)
serious medical problems such as heart or renal failure; and
(d) coexisting severe stenosis or occlusion of the M2 or M3
segments of the MCA. In two patients, the selected stent was
not able to reach the target because of extreme tortuosity;
these patients were excluded from further analysis. The
patient population was composed of seven male and five
female subjects (age range 42–76 years; mean 58 years). All
patients had a stenotic lesion that was considered to be
directly responsible for the symptoms, and they were selected
for stent assisted angioplasty on the basis of several factors,
including failure or contraindication of medical treatment;
non-feasibility, failure, or contraindication of surgery; poor
neurological grade; and poor medical status. The patient’s
family gave informed written consent for cerebral arterio-
graphy, intracranial balloon angioplasty, and intracranial
artery stent placement.
Patients received aspirin and clopidogrel (Plavix; Sanofi)
72 hours before the procedure, combined therapy was
continued for 6 months, and aspirin was continued indefi-
nitely. All the patients underwent pre-operative CT or MR
imaging or both and cerebral digital subtraction angiography.
Eleven of 14 patients underwent pre-operatively brain 99mTc-
exametazime (Ceretec; Amersham) SPECT. Seven of 11
patients post-operatively underwent SPECT scans within
1 week of surgery. Angiographic follow up was conducted at
6 and 12 months. No patient was lost to follow up
monitoring except one who died. Employing the criteria
developed by the Warfarin–Aspirin Symptomatic Intracranial
Disease study,15 16 we calculated the stenosis rate on
angiograms before and immediately after stent assisted
angioplasty and at follow up to compare the diameter of
the vessel at the site of greatest narrowing with the diameter
of a normal artery distal to the lesion. A technically successful
stent assisted angioplasty was defined as one leaving a
residual stenosis of 50% or less without any serious
complications. The post-operative neurological and func-
tional status was evaluated by two neurologists at intervals of
2 months. To assess the post-operative functional status at
admission, at discharge and at last follow up respectively, we
defined a 6 point scale (modified Rankin Scale17).
Procedure
The length and diameter of a lesion were measured on
arteriograms obtained with the lesion positioned at the
isocentre. Because images obtained with digital subtraction
angiography in our institution showed lesions to be 1.4 times
larger at the isocentre, a 14 mm scale was placed on an image
intensifier entrance plane with a grid to indicate a 10 mm
scale on the angiograms. Before, during, and after translum-
inal stent assisted angioplasty for stenosis, patients were
given heparin intravenously (activated partial thromboplas-
tin time 2–3 times baseline) to avoid thrombus formation,
and isosorbide dinitrate (1.25 to 2.50 mg) was injected as a
single rapid bolus into the internal carotid artery (ICA)
through a guiding catheter (8F MPA; Cordis Co. Miami, FL,
USA) to prevent catheter induced vasospasm. All procedures
were performed under neuroleptic anaesthesia with propo-
fol. A 0.014 inch guide wire (Wizdom-14; Cordis Co) was
navigated across the target site. The S-660 stents (Medtronic-
AVE, Santa Rosa, CA, USA) were used in all cases except in
the first case which used the GFX coronary stent (AVE Inc.,
Santa Rosa, CA, USA). The main principle of stent placement
was that a balloon of a smaller size than the diameter of the
vessel should be gradually dilated with lower than nominal
pressure. The stent was deployed at 5–8 Å below the nominal
pressure for 20–30 seconds. After the balloon was deflated,
the result was verified and, eventually, inflation was repeated
(fig 1). After the intervention, each patient underwent a
complete neurological examination, after which their
neurological status was monitored closely for 24 hours.
Heparinisation was discontinued after 24 hours post-treat-
ment but was not reversed by the antidote. The sheath used
to introduce the stent into the artery was removed after the
procedure.
Statistical analysis
Data analysis was performed by using SPSS/Windows version
10.0 statistical software; statistical significance was set at
p,0.001 (two tailed assessment). Paired Student’s t test was
used to determine whether there were any differences in
percentage diameter stenosis on the angiograms obtained




The demographic and clinical features of the patients are
presented in table 1. Lesion laterality is 1:2 (right:left), mean
lesion length 6.4 mm (range 3–14 mm). Brain SPECT
showed decreased perfusion in the affected MCA territory
in all the tested patients with TIAs. In five stroke patients,
Figure 1 Stent assisted angioplasty for the symptomatic left middle
cerebral artery stenosis (Type B according to Mori’s classification). (A)
Initial angiogram shows a high grade (90%), eccentric, focal (length 5–
10 mm), arteriosclerotic stenosis of the left M1 segment. (B) Follow up
angiogram obtained after 12 months demonstrates no signs of
restenosis. (C) Brain 99mTc-exametazime (Ceretec; Amersham) single
photon emission computed tomographic (SPECT) scans show diffusely
reduced perfusion in the left cerebral hemisphere pre-operatively. (D)
Follow up SPECT scan obtained within 24 hours after stent deployment
had improved to nearly normal perfusion.
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brain MRI and SPECT findings were consistent with infarcts
at the MCA border zone territory, which were probably
related to haemodynamic insufficiency: internal border zone
infarction in one patient, and cortical border zone infarction
(between anterior cerebral artery and MCA, and between
posterior cerebral artery and MCA) in four. Six lesions (50%)
were classified as type A; four (33%), as type B; and two
(17%), as type C.
Immediate outcomes
The overall success in reaching the target lesion with
stents was 85.7% (of 14 targets). Two procedures (cases 6
and 10) were abandoned because the tortuosity of the
blood vessel made it impossible to manipulate the device.
Apart from case 4, all patients were treated with one stent
each (11 cases; 91.7%). Pre-procedural stenosis varied from
80% to 95% (mean 88%), and post-operative residual steno-
sis varied from 0% to 15% (mean 6.5%) (p,0.001) (fig 2).
Four patients were complicated. Two patients (cases 1
and 4) had arterial rupture related to morbidity and
mortality. In case 4, the target vessel ruptured intra-
operatively. Complete coverage of the lesion and emergent
rescue of the ruptured vessel required the implantation
of a second abutted stent, and the patient recovered with
minor neurological deficit. The other patient (case 1) died
3 days later. Of the other two patients, an acute throm-
botic occlusion was managed in case 7 by intra-arterial
administration of abciximab (Reopro; Centocor, Malvern, PA,
USA), but the pre-existing neurological deficit was not
aggravated. Case 12, who had distal thrombosis during the
procedure, had fixed neurological deficits despite heparinisa-
tion. The global morbidity rate related to the procedure
was 33.3% (four of 12), and the mortality rate was 8.3% (one
of 12).
Follow up outcomes
Angiographic follow up varied from 7 to 24 months. No
evidence of angiographic in stent de novo stenosis or
recurrence of stenosis was seen in all eight cases who were
followed up angiographically for at least 6 months. All six
patients who underwent follow up cerebral angiography at
12 months had no recurrence of stenosis (fig 2).
Comparing with previous SPECT scans, diffusely decreased
perfusion of the cerebral hemisphere was restored and the
focal perfusion defect disappeared almost completely in










size (mm) Inflation pressure
Follow up
SPECT finding Complications
1 54/M Recurrent TIAs Aspirin ND A GFX 3.569 8 Å for 3 seconds ND Arterial rupture
2 72/M Recurrent TIAs Aspirin/clopidogrel Perfusion
defect
B S-660 2.569 6 Åfor 20 seconds Improved
perfusion
None
3 62/F Two strokes Aspirin/ticlopidine Perfusion
defect
B S-660 2.5612 6 Å for 15 seconds No change None
4 42/F Recurrent TIAs Aspirin Perfusion
defect




S-660 2.5618 Endovascular rescue
5 68/M Hemiparesis Aspirin ND A S-660 2.569 6 Å for 20 seconds ND None
6 56/M Recurrent TIAs Aspirin Perfusion
defect
B – – ND –
7 76/M Two strokes Warfarin ND B S-660 2.5615 6 Å for 20 seconds ND Thrombotic occlusion
8 56/M Recurrent TIAs Aspirin/ticlopidine Perfusion
defect
A S-660 2.569 6 Å for 15 seconds Improved
perfusion
None
9 67/F Hemiparesis Warfarin Perfusion
defect
B S-660 2.5615 6 Å for 20 seconds Improved
perfusion
None
10 70/F Two strokes Clopidogrel Perfusion
defect
C – – ND –
11 58/M Recurrent TIAs Aspirin/clopidogrel Perfusion
defect
A S-660 2.569 6 Å for 10 seconds Improved
perfusion
None
12 62/F Hemiparesis Warfarin/aspirin Perfusion
defect
C S-660 2.5618 5 Å for 30 seconds ND Distal thrombosis
13 67/M Hemiparesis Aspirin/ticlopidine Perfusion
defect
A S-660 2.569 6 Å for 20 seconds No change None
14 58/F Recurrent TIAs Aspirin Perfusion
defect
A S-660 2.569 6 Å for 10 seconds Improved
perfusion
None
Medication: pre-operative medication (antiplatelets and/or anticoagulants).
Lesion type: classified according to the method of Mori et al.8
ND, not done; TIAs, transient ischaemic deficits; complication, periprocedural and post-procedural complications; endovascular rescue, arterial rupture was
rescued by balloon tamponade and additional overlapping stenting.
Thrombotic occlusion was treated with intra-arterial administration of abciximab (Reopro; Centocor, Malvern, PA).
Cases 6 and 10 had unsuccessful stent assisted angioplasty owing to the tortuouity of the internal carotid artery siphon.
Figure 2 Changes in the diameter of the stenotic middle artery on the
angiograms obtained before (pre-SAA) and immediately after (post-
SAA) treatment and at the 6 month (6M-SAA), and last (Last-SAA)
follow ups. There was significant reduction of the stenosis between the
pre-operative and post-operative follow up angiograms (p,0.001,
paired Student’s t test). All eight patients who underwent follow up
cerebral angiography had no recurrence of stenosis.
Elective stenting for middle cerebral artery stenosis 849
www.jnnp.com
follow up SPECT scans of all four patients with TIAs (fig 1).
In three stroke patients who underwent follow up SPECT,
improved perfusion was demonstrated in only one; the
remaining two showed no improvement (table 1).
The clinical follow up period varied from 3 to 27 months
(mean 11 month). Good short term clinical outcomes of the
successful stent assisted angioplasties were achieved in eight
patients (66.7%). None of the five patients (cases 2, 4, 8, 11,
and 14) who had had recurrent TIAs developed additional
TIAs during the follow up period. None of the six patients
(cases 3, 5, 7, 9, 12, and 13) who had had one or more stroke
attacks developed additional ischaemic stroke during the
follow up period. On the modified Rankin Scale applied in
follow up, 4/5 TIA patients and 5/6 stroke patients who
underwent the successful procedure were assessed as func-
tionally improved or of stable clinical status. Of the five stroke
patients (cases 3, 5, 7, 9, and 13) who had clinically stable or
improved status, one (case 5) showed clinical improvement at
discharge (the motor dysfunction resolved), one (case 9)
revealed motor improvement over a 6 month period, and the
remaining three (cases 3, 7, and 13) did not show any clinical
improvement during follow up. The TIA group had relatively
poorer prognosis than the stroke group (fig 3). No patient died
during the follow up period. Of the two patients where surgery
had failed to gain access to the MCA because of the tortuosity
of the ICA siphon, one patient (case 6), who had experienced
TIAs, developed a complete MCA infarction 9 months after
discharge. The other stroke patient (case 10) was clinically
stable up to the 1 year follow up.
DISCUSSION
The natural history of intracranial stenoses has not been as
well studied as that of extracranial stenoses, but they are
consistently associated with a high stroke rate.18 19 Stenoses
of the MCA occur at a rate of at least 8% per year.3 4 This
study by Bogousslavsky et al3 revealed that 58% of the Asian
population enrolled in the extracranial–intracranial (EC-IC)
bypass study were eligible for the MCA arteriosclerosis study,
whereas only 34% of blacks and only 18% of whites were
eligible, emphasising the ethnic differences in this disease.
Only about one third of patients had a warning TIA prior to
stroke; the remaining two thirds did not.3 20
Management of these high risk patients is controversial.
Recently, PTA has been performed in patients refractory to
medical treatment, and several reports have been published
concerning the usefulness of angioplasty in the treatment of
arteriosclerotic stenosis of the MCA.6–8 21 However, compared
with extracranial vessels, angioplasty of intracranial vessels
has a higher complication rate. PTA has had problems of
abrupt closure owing to complications such as intimal
damage, elastic recoil, and thrombosis. Mori et al8 reported
a clinical success rate of 92%, 86%, and 33% for PTA of
intracranial lesions of Type A, B, and C, respectively. At
1 year follow up, rates of stenosis recurrence of 0%, 33%, and
100%, respectively, were seen. Stent placement for refractory
intracranial stenosis has been developed because of sub-
optimal long term results after balloon angioplasty alone.
Although no evidence exists to demonstrate the superiority of
stent placement over angioplasty alone in the intracranial
circulation, available data indicate that it is superior for
coronary vessels of similar calibre to the intracranial vessels.
In one study of 43 lesions in coronary vessels less than
2.5 mm in calibre, 76% of patients remained symptom free or
had patent target sites after coronary artery stent place-
ment.22 Theoretically, stenting minimises the risk of acute
closure caused by compression of the intimal flap, and in
trapping plaque material between the stent and the vessel
wall, can act as a barrier to platelet aggregation of plaque.
The risk of vessel rupture may also be reduced, as the stent
may provide additional wall support. Therefore, stenting is
considered the better tool for vascular recanalisation than
PTA.
The purpose of stent assisted angioplasty should be to
provide sufficient perfusion to reduce ischaemic symptoms,
not to provide an angiographic cure.23 Improved clinical
outcome was defined as ‘stable or improved neurological
status and resolution of progressive or recurring symptoms’.
Considering that none of the five patients with recurrent TIAs
and none of the six patients who had experienced one or
more stroke attacks developed TIAs or additional ischaemic
stroke during the follow up period, there appears to be a
therapeutic efficacy of stenting. The clinical improvement
might have been related to improved perfusion to the
ischaemic penumbra zone or developed collateral circulation
in the stroke patients. SPECT scans demonstrated improved
baseline cerebral perfusion and marked augmentation of
cerebral blood flow in the MCA distribution after acetazol-
amide administration.24 In our study, follow up brain SPECT
of four patients with TIA showed improved perfusion in the
MCA region. Improved regional blood flow was demon-
strated in SPECT despite the one documented stroke patient.
It is possible that stent assisted angioplasty might have
resulted in development of new collateral channels. Other
benefits of revascularisation include reduced stroke risk as a
result of normalisation of oxygen extraction fraction and
increased cerebral blood flow.25 In our series, most patients
with TIAs had improvement in their ischaemic symptoms
immediately after stenting and had augmented cerebral flow,
which was demonstrated by cerebral arteriography and
SPECT.
Problems with stenting are re-stenosis and acute occlusion.
Clearly, stenting of smaller vessels is accompanied by a
greater potential for recurrence of stenosis. In our study,
there was no recurrence during a short term follow up period.
However, there are few reports in the literature concerning
intracranial stent patency. The accumulative experience with
coronary artery stenting of a small calibre tube (,2.5 mm) is
very important in understanding the fate of the stent in the
proximal portion of the MCA. The results of the Stent
Restenosis Study for coronary vessels stenosis (,3 mm)
showed a stenosis recurrence rate of 50% or more in 55% of
the angioplasty group and in 34% of the group receiving
stents.26 Small vessel stenting for coronary vessels is
associated with a higher stenosis recurrence rate and worse
Figure 3 Clinical outcome on the modified Rankin Scale. The transient
ischaemic deficits group (black lines) had relatively poorer prognosis
than the stroke group (green lines). However, there was a generally
stable or improved clinical status after stent assisted angioplasty. Red
lines indicate the clinical course of two patients in whom surgery was
unsuccessful due to the tortuous curve of the internal carotid artery
siphon. One patient who had experienced transient ischaemic deficits
developed a complete middle cerebral artery infarction 9 months after
discharge.
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event free survival rate.27 28 Additionally, the smaller lumen of
the vessel increases the likelihood of acute thrombosis with
complicating ischaemia. We experienced several complica-
tions of arterial rupture and thrombosis related to mortality
and morbidity. Balloon overdilation is not an accepted
practice in the intracranial circulation, and it may be
especially dangerous in the basilar artery or the MCA, where
different authors advocate underdilation because of the
insubstantial muscularis and adventitial layers of the artery
wall and the subsequent elevated risk of perforation.21 The S-
660 stent we used was a balloon expandable stent and its
nominal pressure was 8 Å, but the balloon was inflated to a
maximum pressure of 6 Å to ensure stent detachment in our
series.
CONCLUSIONS
Although the rate of stenosis recurrence in stent assisted
angioplasty in our study seems to be better than that for PTA
reported previously, the complication rate of stent assisted
angioplasty is higher than the known annual risk of
ipsilateral stroke. Although elective stenting is a worthwhile
therapeutic method for the prevention of secondary ischae-
mic stroke in strokes, it seems to be a potentially effective but
also hazardous therapeutic technique in patients with
recurrent TIAs due to MCA stenosis. Long term follow up
data and additional clinical experience are required to
properly assess this novel approach for treatment of MCA
stenosis. Whether this will lead to better outcomes and
reduce stroke risk for MCA stenosis in the future remains
unclear. It indicates the need for randomised control trial
data of this intervention.
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